Clinical TrialJul 1, 2026, 08:02 AM
Evaxion to Present Preclinical Data for CMV Vaccine EVX-V1
AI Summary
Evaxion A/S announced it will present new preclinical data for its vaccine candidate EVX-V1 at the International Herpesvirus Workshop 2026. This data is crucial for guiding the final antigen selection for a broadly protective cytomegalovirus (CMV) vaccine. EVX-V1 is an AI-driven, multi-component vaccine designed to address CMV, a widespread infection with a significant market size, valued at $474.6 million in 2023 and projected to grow at a 6.6% CAGR.
Key Highlights
- Evaxion to present new preclinical data for vaccine candidate EVX-V1 at the International Herpesvirus Workshop 2026.
- The new preclinical data will guide final antigen selection for a broadly protective CMV vaccine candidate.
- EVX-V1 is a next-generation, multi-component cytomegalovirus (CMV) vaccine candidate using AI-Immunology™ platform.
- CMV infects 60-70% of adults in developed countries and nearly 100% in developing economies.
- The CMV treatment market was valued at $474.6 million in 2023, projected to grow at 6.6% CAGR (2024-2032).
- Presentation details: July 12, 2026, at 9:30-11:30am ET in Montreal, Canada.
Price Impact
More from EVAX